New shot every 12 weeks could help men with advanced prostate cancer

NCT ID NCT04729114

Recruiting now Disease control Sponsor: Astellas Pharma Global Development, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new medicine called PRL-02 depot, given as a shot into the muscle every 12 weeks, for men with advanced prostate cancer. The drug lowers testosterone, which can help control the cancer. The study aims to find a safe dose and see how well men tolerate it, either alone or with other drugs like enzalutamide. About 174 men whose cancer has returned or not responded to prior treatment will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma Neoplasm Metastasis prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER PROSTATE CANCER

Contacts and locations

Locations

Arizona Urology Specialists
WITHDRAWN

Tucson, Arizona, 85715, United States
Carolina Urologic Research Center
RECRUITING

Myrtle Beach, South Carolina, 29572, United States
Chesapeake Urology
RECRUITING

Towson, Maryland, 21204, United States
Duke Cancer Center
RECRUITING

Durham, North Carolina, 27710, United States
First Urology
RECRUITING

Jeffersonville, Indiana, 47130, United States
Florida Urology Partners
WITHDRAWN

Tampa, Florida, 33609, United States
Fort Wayne Medical Oncology and Hematology, Inc.
WITHDRAWN

Fort Wayne, Indiana, 46804, United States
Garden Sate Urology
WITHDRAWN

Morristown, New Jersey, 07960, United States
Helios Clinical Research, LLC
WITHDRAWN

Middleburg Heights, Ohio, 44130, United States
Houston Metro Urology
RECRUITING

Houston, Texas, 77027, United States
Los Angeles Cancer Network
RECRUITING

Anaheim, California, 92801, United States
MidLantic Urology
RECRUITING

Bala-Cynwyd, Pennsylvania, 19004, United States
National Cancer Institute
WITHDRAWN

Bethesda, Maryland, 20892, United States
New Mexico Oncology Hematology Consultants Ltd
RECRUITING

Albuquerque, New Mexico, 87109, United States
Northwest Medical Specialties
RECRUITING

Tacoma, Washington, 98405, United States
Oncology Consultants
WITHDRAWN

Houston, Texas, 77030, United States
Pan American Center for Oncology Trials, LLC
RECRUITING

San Juan, Rio Piedras, 00935, Puerto Rico
Providence Medical Group Oncology Santa Rosa
RECRUITING

Santa Rosa, California, 95403, United States
Toledo Clinical Cancer Center
WITHDRAWN

Toledo, Ohio, 43623, United States
University of Virginia Cancer Center
RECRUITING

Charlottesville, Virginia, 22908, United States
Urology Associates PC
RECRUITING

Nashville, Tennessee, 37209, United States
Urology Clinics of North Texas
RECRUITING

Dallas, Texas, 75231, United States
Urology San Antonio
WITHDRAWN

San Antonio, Texas, 78229, United States
Wichita Urology Group
RECRUITING

Wichita, Kansas, 67226, United States
XCancer Center Omaha/Urology Cancer Center
COMPLETED

Omaha, Nebraska, 68130, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.